Lilly introduces Zepbound vials in US at 50% off

Eli Lilly has fulfilled its commitment to launching Zepbound (tirzepatide) in 2.5 mg and 5 mg single-dose vials in the United States, aiming to significantly increase the supply of the dual GIP/GLP-1 agonist amid high demand. Announcing the launch on Tuesday, the pharmaceutical company revealed that these single-dose vials are available at a 50% or more discount compared to other incretin medicines for obesity. 

The pricing for Zepbound’s new single-dose vials is set at $399 for a four-week supply of the 2.5 mg dose and $549 for the 5 mg dose. This pricing strategy is aimed at enhancing accessibility for individuals ineligible for the Zepbound savings card program or lacking employer insurance coverage. Eli Lilly emphasized that this initiative enables self-paying patients to bypass third-party supply chain entities, thereby accessing savings directly without involving insurance.

Patrik Jonsson, president of Lilly cardiometabolic health and Lilly USA, highlighted the dual benefits of these new vials. "These new vials not only help us meet the high demand for our obesity medicine but also broaden access for patients seeking a safe and effective treatment option," Jonsson said. The vials can be purchased through LillyDirect by patients with a valid, on-label prescription.

Jonsson also pointed out that obesity is often misclassified as a lifestyle choice rather than a serious chronic illness, leading many employers and the federal government to exclude medications like Zepbound from insurance coverage. He stressed that outdated policies and a lack of coverage for obesity medications necessitate more innovative solutions.

Zepbound received FDA approval last November as a weekly injectable treatment for adults with obesity or those who are overweight and have at least one weight-related condition. The list price for a month’s supply was initially set at approximately $1060.

Despite being on the market for only a short period and facing initial supply constraints, Zepbound has quickly achieved blockbuster status. Eli Lilly recently reported that the drug generated $1.2 billion in sales in the second quarter. To meet the growing demand, the company has invested significantly in expanding production capacity, committing $5.3 billion to enhance an Indiana manufacturing site, in addition to a previous $3.7 billion investment.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!